Liraglutide
Saxenda · Victoza
A GLP-1 receptor agonist with a fatty-acid chain enabling self-association and albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-daily administration.
Half-life
~13 h, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Marketed as ready-to-use multi-dose prefilled pens; refrigerate before first use, then store per label and protect from light.
References
- FDA labels: Victoza (2010), Saxenda (2014)
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.